

Metir plc Stock Data

Share Price:	1.30p
Market Cap:	£4.03m
Shares in issue:	309.91m
52 week high/low:	1.30p/0.54p

Metir plc Company Profile

Sector:	Electronic & Electrical Equipment
Ticker:	MET
Exchange:	AIM

Activities

Metir plc ('Metir', 'the Company', 'MET'), is an international developer and provider of testing solutions plus related consumables to unique and underserved public health and environmental markets. It provides services through its wholly owned operating subsidiaries, Modern Water (toxicity and pathogen monitoring) and Microsaic Systems (point-of-need contaminant detection).

Website: www.metirplc.com/

Aptamer Group plc Stock Data

Share Price:	1.15p
Market Cap.:	£31.02m
Shares in issue:	2,696.98m
52 week high/low:	1.57p/0.20p

Aptamer Group plc Company Profile

Sector:	Health Care
Ticker:	APTA
Exchange:	AIM

Activities

Aptamer Group plc ('APTA', 'Aptamer') is a leading provider of custom aptamer selection and development services for a wide range of research, diagnostic and therapeutic applications.

Website: www.aptagroup.com

Turner Pope contact details

Tel:	0203 657 0050
Email:	info@turnerpope.com
Web:	www.turnerpope.com

Andrew Thacker
Corporate Broking & Sales

Barry Gibb
Research Analyst

TPI acts as Joint Broker to Metir plc and Broker to Aptamer Group plc.

Attention is drawn to the disclaimers and risk warnings at the end of this document.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Metir plc Aptamer Group plc

Metir has announced a new contract with Aptamer Group plc for the development of Optimer® binders for rapid Cryptosporidium detection using its next-generation, pathogen monitoring platform. For Metir, this collaboration (the 'Collaboration') represents an important step forward in its strategy to deliver a market-leading, real-time water monitoring solution. For Aptamer, it commences a development agreement first established with Metir on 14 June 2024 for creation of new binders capable of targeting multiple water-borne pathogens. Providing high specificity for accurate identification of contamination/reduction of false positives, the exceptional stability of aptamers also provides the robustness required for continuous monitoring in real-world water systems. The technology's adaptability creates future opportunity for multiplexed detection in response to customers' evolving needs, while synthetic manufacturing ensures a secure, scalable and reproducible supply chain. Being one of the final technical milestones for Metir's device, proof-of-concept data is expected within three months; subject to successful development and financing, this important new product line could be ready for field-testing by the end of 2026. With several UK water companies having already indicated their interest in trialling when it becomes available, today's Collaboration offers potential for Metir to rapidly expand its global footprint across the growing environmental and water testing sectors. No financial details have been disclosed, although Aptamer's strategy of retaining all intellectual property rights for its developed binders (therein strengthening its proprietary portfolio), suggests a future licensing and/or royalty payments may become due upon commercialisation.

Global need for a robust Cryptosporidium monitoring solution

Cryptosporidium is a common waterborne parasite that poses a significant risk to public health worldwide. The World Health Organisation ('WHO') cites it as a leading cause of diarrhoeal disease, while outbreaks in the UK and the USA highlight the ongoing need for robust monitoring solutions. According to Grand View Research, the global water quality monitoring market is forecast to exceed US\$6 billion by 2030, while Market Research Intellect projects the Cryptosporidium diagnostic testing market to expand from US\$289 million in 2024 to reach US\$496 million by 2033. Together these suggest significant future commercial opportunity for advanced detection systems helping industries, utilities, and regulators monitor safety and compliance in real-time.

Cryptosporidium poses a challenge to water treatment processes because of its small size, resistance to disinfection processes (like chlorination) and the fact that it can withstand up to 16 months of environmental stress. Current monitoring processes are complex and can take up to 48 hours to turn around with varying degrees of accuracy. Recognising the urgent need for utility groups to improve their detection capabilities, funding has already been pledged through the UK's Water Services Regulation Authority's ('Ofwat') Breakthrough Challenge to develop an on-line automated system. This project is being led by Severn Trent Water and partnered with a number of

other UK utilities/institutions. Having already taken development of its next generation detection platform to an advanced stage of development, successful integration of the proposed Optimer® binders creates opportunity for Metir to deliver an ideal solution for adoption by these water companies and other bodies/industries needing fast response warnings, to potentially capture a substantial share of the newly identified market opportunity.


Optimer® binders tailored for Metir's pathogen detector platform

Aptamer has been contracted to deliver a staged programme of feasibility, isolation and optimisation work to generate Optimer® binders tailored for Metir's pathogen detector platform. Manufacture of the Cryptosporidium Optimer® is one of the final technical stages for commercialisation beyond the current status, with several prototypes having already been built for Covid-19 detection in water. The technology's integration into Metir's device is expected to deliver substantial benefits over existing solutions; these include faster and more reliable results using synthetic, laboratory-made binders that ensure consistency of performance, while their exceptional stability means that it is sufficiently robust/operationally suited for continuous monitoring in real-world water systems. It is also adaptable for multiplexed detection of additional pathogens and, given that Optimers® are chemically manufactured rather than biologically derived, offer a secure, scalable and reproducible supply chain.

Proof-of-concept data is expected within three months, with potential for further development into a multiplexed pathogen detection system in the future as might be required. Metir's important new product line could be ready for field-testing by the end of 2026, subject to successful development and financing.

Metir – Responding to increasing customer demand with innovative product development

Metir's half year (to end-June 2025) cash balance of £586,000 was materially improved following its successful £703,000 (net) equity fundraise that closed on 10 June 2025, which was followed by an additional Director's subscription of £70,000 on 21 July 2025. It reported a strong revenue performance during the Interim period, driven by increased demand for its MicroTox® LX instruments and growing volume of reagent sales. With demand expected to be sustained throughout the second half, cash burn is likely to have substantially reduced from the levels experienced during last year's restructuring phase. Now committed to increasing its market share/expanding its global footprint across the growing environmental and water testing sectors, the Company is able to invest prudently in infrastructure while also increasing sales/marketing activity. This includes pursuing major water testing opportunities, similar to the Continuous Toxic Monitoring ('CTM') deployment it is completing in Qatar, as well as commercialising its latest innovations. Reflecting confidence in Metir's future outlook and market positioning, Acting Executive Chairman and Chief Executive Officer, Bob Moore, noted in an Interim Trading Update published on 31 July 2025, that "The Board is encouraged by the strong sales performance achieved in the first half of 2025 and remains firmly focused on scaling revenue, enhancing gross margins and progressing towards sustainable cash generation."



Please note: Past share price performance is no guide to future share price performance

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document. Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as joint broker to Metir plc ('Metir') and broker to Aptamer Group plc ('Aptamer') which are both listed on the AIM Market of the London Stock Exchange ('AIM').

TPI's private and institutional clients may hold, subscribe for or buy or sell Metir and/or Aptamer securities. Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Metir or Aptamer.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2025 Turner Pope Investments (TPI) Limited, all rights reserved.